Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Gain Therapeutics, Inc. (NASDAQ:GANX) has received a consensus rating of "Buy" from six analysts, with an average twelve-month price target of $8.00.
• The company recently reported earnings of ($0.19) per share for the last quarter, missing analysts' expectations.
• Major institutional investors have increased their stakes in Gain Therapeutics, with Marshall Wace LLP growing its position by 41.0% during the 2nd quarter.

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $8.00.

A number of equities analysts have recently issued reports on GANX shares. BTIG Research reissued a "buy" rating and issued a $9.00 target price on shares of Gain Therapeutics in a report on Monday, September 8th. Roth Capital dropped their target price on Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Thursday, July 3rd.

Gain Therapeutics Trading Up 0.6%

Gain Therapeutics stock opened at $1.75 on Wednesday. The business has a 50 day moving average price of $1.68 and a two-hundred day moving average price of $1.81. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.09. The stock has a market cap of $62.91 million, a price-to-earnings ratio of -2.78 and a beta of 0.14. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $3.19.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). As a group, equities analysts forecast that Gain Therapeutics will post -1 EPS for the current year.

Institutional Investors Weigh In On Gain Therapeutics

A number of large investors have recently bought and sold shares of the business. Marshall Wace LLP grew its position in Gain Therapeutics by 41.0% during the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock worth $498,000 after acquiring an additional 80,407 shares during the last quarter. Geode Capital Management LLC grew its position in Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock worth $523,000 after acquiring an additional 8,251 shares during the last quarter. Kovitz Investment Group Partners LLC bought a new stake in Gain Therapeutics during the 1st quarter worth approximately $91,000. Dauntless Investment Group LLC bought a new stake in Gain Therapeutics during the 1st quarter worth approximately $240,000. Finally, Northern Trust Corp grew its position in Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company's stock worth $183,000 after acquiring an additional 39,642 shares during the last quarter. 11.97% of the stock is currently owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.